Keeton T K, Pettinger W A, Campbell W B
Circ Res. 1976 Jun;38(6):531-9. doi: 10.1161/01.res.38.6.531.
Circulating angiotensin II is said to inhibit renin release by a direct, intrarenal action. This effect of angiotensin was studied indirectly using the selective angiotensin II antagonist saralasin (1Sar-8-Ala-angiotensin II) in conscious normal, sodium-depleted, and sodium-loaded rats. Saralasin caused a dose-related increase in plasma renin concentration (PRC) in normal and sodium-depleted rats, but had no effect on PRC in sodium-loaded animals. However, saralasin was 300 times more active in sodium-depleted rats than in normal rats. Saralasin caused hypotension and tachycardia in sodium-depleted rats, but not in normals. Propranolol inhibited saralasin-induced renin release by 99% in normal rats and by 75% in sodium-depleted rats but not alter the hypotensive effect of saralasin in the latter. Saralasin potentiated phentolamine-induced renin release, hypotension, and tachycardia in normal rats, and this potentiated renin release was blocked by propranolol. We conclude that a portion of saralasin-elicited renin release in sodium-depleted rats is mediated by hypotensive activation of the carotid baroreceptor reflex which increases sympathetic nervous activity in the kidney. However, in sodium-depleted rats saralasin induced a 42-fold increase in PRC, whereas an equipotent hypotensive dose of the vasodilator hydralazine caused only a 3.5-fold increase in PRC. Thus, we find that saralasin appears to have a selective effect on renin release over and above its hypotensive effect, which suggests an angiotensin-mediated, feedback mechanism inhibitory to renin release. Thus, we have come to the conclusion that for part of saralasin-induced renin release appears to be caused by disinhibition of angiotensin suppression of renin secretion. This "short-loop" feed-back mechanism is closely associated with intrarenal beta-adrenergic receptors, since propranolol impaired saralasin-induced renin release under all circumstances in our experiments.
据说循环中的血管紧张素II通过直接的肾内作用抑制肾素释放。在清醒的正常、缺钠和钠负荷大鼠中,使用选择性血管紧张素II拮抗剂沙拉新(1-沙拉氨酰-8-丙氨酰血管紧张素II)间接研究了血管紧张素的这种作用。沙拉新使正常和缺钠大鼠的血浆肾素浓度(PRC)呈剂量相关增加,但对钠负荷动物的PRC无影响。然而,沙拉新在缺钠大鼠中的活性比正常大鼠高300倍。沙拉新使缺钠大鼠出现低血压和心动过速,但正常大鼠未出现。普萘洛尔在正常大鼠中可抑制沙拉新诱导的肾素释放达99%,在缺钠大鼠中可抑制75%,但不改变沙拉新对后者的降压作用。沙拉新增强了酚妥拉明在正常大鼠中诱导的肾素释放、低血压和心动过速,而这种增强的肾素释放被普萘洛尔阻断。我们得出结论,缺钠大鼠中沙拉新引发的部分肾素释放是由颈动脉压力感受器反射的降压激活介导的,该反射增加了肾内交感神经活动。然而,在缺钠大鼠中,沙拉新使PRC增加了42倍,而等效降压剂量的血管扩张剂肼屈嗪仅使PRC增加了3.5倍。因此,我们发现沙拉新除降压作用外,似乎对肾素释放有选择性作用,这表明存在一种血管紧张素介导的、抑制肾素释放的反馈机制。因此,我们得出结论,沙拉新诱导的部分肾素释放似乎是由于血管紧张素对肾素分泌的抑制作用解除所致。这种“短环”反馈机制与肾内β-肾上腺素能受体密切相关,因为在我们的实验中,普萘洛尔在所有情况下均损害了沙拉新诱导的肾素释放。